新发心房颤动:挑战与机遇
本文综述了新发心房颤动的管理挑战与机遇。由于公众自我筛查、人群筛查和植入设备监测,房颤常在低负荷、合并症少或早期阶段被诊断。指南传统上侧重抗凝和心室率控制,AF-SCREEN协作组提出积极管理新发房颤可能合理,包括合并症和生活方式管理以及积极节律控制±抗凝,但缺乏有力证据,需创新性研究。
要点
- 新发房颤常为低负荷且合并症少或处于早期,管理重要性日益增加。
- 指南传统侧重抗凝预防血栓和心室率控制缓解症状,新指南更重视生活方式和合并症管理。
- AF-SCREEN协作组提出积极管理新发房颤可能合理,包括合并症管理、健康生活方式、积极节律控制±抗凝。
核心结论
- 新发房颤的积极管理(合并症和生活方式管理、积极节律控制±抗凝)可能有益,但缺乏有力证据,需创新性研究确定早期积极治疗的价值和风险。
研究设计与样本
- 本文为综述,未报告系统检索范围。
主要发现
- 房颤常在首次发作附近被早期诊断,原因包括公众自我筛查意识提高、人群筛查和机会性病例发现等医疗举措以及植入式心脏设备使用和监测增加。
- 新发房颤常为低负荷,心血管合并症可能不存在或处于早期。
- 指南传统上侧重抗凝血栓预防,一般推荐谨慎的节律控制,并优先心室率控制以缓解症状;新指南更重视生活方式和合并症管理。
- AF-SCREEN协作组提出积极管理新发房颤可能合理,包括管理合并症和促进健康生活方式以预防房颤和相關心血管疾病的发生或进展,以及启动积极节律控制±抗凝以预防房颤相关发病和死亡(包括卒中和心衰)。
- 在已确诊房颤患者中,生活方式和合并症管理、节律控制和抗凝是改善结局的重要贡献因素,但新发房颤缺乏有力证据。
临床怎么用
- 临床应重视新发房颤的早期识别,评估房颤负荷和合并症,考虑生活方式和合并症管理。
- 根据指南传统,抗凝用于血栓预防,心室率控制用于缓解症状,节律控制需谨慎选择。
- 对于新发房颤,可考虑积极节律控制±抗凝以预防卒中和心衰,但需权衡获益与干预并发症和潜在不良反应。
局限性
- 新发房颤缺乏有力证据,需更多数据指导最佳管理,并考虑房颤负荷。
- 需长期研究利用大型国家数据库链接电子病历和节律监测设备,以及短期研究聚焦降低房颤负荷延缓进展和心衰等结局,可在随机临床试验和观察性队列研究中进行。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Atrial fibrillation (AF) is increasingly diagnosed early, close to its first occurrence due to: (i) increased public awareness with self-screening; (ii) health care initiatives including population screening and opportunistic case finding; and (iii) increased use and surveillance of implantable cardiac devices. At its onset, AF is often low burden, and cardiovascular co-morbidities may be absent or at an early stage. Thus, the management of recent-onset AF has become an issue of growing importance. Professional guidelines have traditionally focused on anticoagulant thromboprophylaxis, generally recommending a cautious approach to rhythm control, and priority has been given to rate control to alleviate symptoms. In recent guidelines, the importance of managing lifestyle and co-morbidities has increased. The AF-SCREEN collaboration proposes that a vigorous approach to active management of recent-onset AF may be warranted. This includes addressing co-morbidities and promoting healthy lifestyles to prevent the emergence or progression of AF and associated cardiovascular disease, as well as the initiation of active rhythm control ± anticoagulation to prevent AF-related morbidity and mortality, including stroke and heart failure (HF). Intuitively, intervention early after AF onset would be beneficial since lifestyle and co-morbidity management, plus rhythm control and anticoagulation, are important contributors to improved outcomes in patients with established AF, but robust evidence is lacking for recent-onset AF. There is a delicate balance between achieving favourable outcomes such as preventing strokes, HF and AF progression vs the complications and potential adverse effects of interventions. Given the serious long-term consequences, innovative approaches are necessary to determine the value and risks of initiating active therapy very early in the course of AF. More data are needed to guide the best management of recent-onset AF, bearing AF burden in mind. Long-term studies using large national databases linked to electronic medical records and rhythm monitoring devices offer excellent opportunities. Shorter-term studies focusing on reducing AF burden to slow AF progression and studies focusing on outcomes such as HF could be used in both randomized clinical trials and observational cohort studies.
引用
- Svennberg, Freedman, Andrade, et al. Recent-onset atrial fibrillation: challenges and opportunities. Eur Heart J. 2026. PMID: 40873195. doi:10.1093/eurheartj/ehaf478
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。